Posts by Yin, Jiale

A phase II clinical study on the sequential use of Adebrelimab combined with chemotherapy followed by thoracic radiotherapy has garnered widespread attention at ASCO 2024, particularly for its impact on the treatment of extensive-stage small cell lung cancer (ES-SCLC).The results are striking: the regimen significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to existing standards, while maintaining a favorable safety profile. Most notably, this strategy set a new survival benchmark for first-line immunotherapy in SCLC, demonstrating the value of integrating immune checkpoint inhibition with thoracic radiotherapy. This innovative approach represents a major step forward in SCLC treatment and offers renewed hope for patients battling this aggressive disease. In light of these findings, Oncology Frontier invited Academician Jinming Yu to share insights into the study design, key outcomes, and its clinical implications. The following is a summary of his expert commentary.

At ASCO GI 2025, Prof. Ying Yuan shared updated data from the BB+CAPOX Phase II trial, showing a median PFS of 25.3 months in liver-only RAS-mutant MSS mCRC. Prof. Kefeng Ding highlighted the potential of this combo to convert immune-cold tumors into responsive disease.

Histone deacetylases (HDACs) are histone-modifying enzymes that play a key role in regulating epigenetic changes, and they are closely linked to the development and drug resistance of breast cancer. HDAC inhibitors (HDACis) can selectively modulate epigenetic features to control tumor cell proliferation, regulate the cell cycle, and repair DNA damage. As a representative class of epigenetically targeted anti-cancer therapies, HDACis are also recommended by Chinese guidelines as an important treatment option for patients with HR+/HER2- advanced breast cancer who have developed resistance to endocrine therapy. We invited Dr. Qingyuan Zhang from Harbin Medical University Cancer Hospital to share her insights into the current treatment landscape of HR+/HER2- advanced breast cancer and to further explore therapeutic options for patients facing endocrine resistance.

With the continuous advancement of pharmaceutical and medical technologies, novel therapies have steadily extended survival for breast cancer patients. Among them, the combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) has brought transformative improvements in outcomes for patients with hormone receptor-positive/HER2-negative (HR+/HER2−) metastatic breast cancer (MBC). Despite its establishment as the current standard first-line treatment, a significant number of patients still experience disease progression, and therapeutic options after CDK4/6i failure remain limited and without consensus.

The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was held in San Francisco, California, from February 13 to 15. It attracted top experts and scholars in the field of urology from around the world. At this conference, Oncology Frontier invited Dr. Philip Kwong from The University of Hong Kong to share his insights on precision testing and individualized management in metastatic castration-resistant prostate cancer (mCRPC). He believes that precision testing and continuous monitoring are crucial for optimizing treatment strategies for mCRPC, and he particularly emphasized the key role of genetic testing in assessing homologous recombination repair (HRR) status. His insights not only provide important guidance for clinical practice but also bring new perspectives to the individualized treatment of mCRPC.

From March 12 to 15, 2025, the 19th St. Gallen Breast Cancer Conference (SGBCC 2025) was held in Vienna, the City of Music. Leading global experts in breast cancer gathered to discuss cutting-edge advancements and hotly debated topics in breast cancer diagnosis and treatment. At the conference, Dr. Javier Cortés, Head of the International Breast Cancer Center (IBCC) in Barcelona, Spain, delivered an insightful keynote speech titled "New anti-HER2 approaches—moving up to the (neo)adjuvant setting?" Oncology Frontier invited Dr. Javier Cortés to share his perspectives and outlook on (neo)adjuvant therapy for early HER2-positive breast cancer.

CheckMate 649 is the first global Phase III trial to successfully evaluate a first-line immunotherapy regimen (nivolumab + chemotherapy) for advanced gastric cancer. The study’s primary results were first unveiled at the 2020 European Society for Medical Oncology (ESMO) Congress, and the pre-specified China subgroup data were presented for the first time at the 2021 American Association for Cancer Research (AACR) meeting. The findings demonstrated even greater benefits in Chinese patients compared to the global population, generating significant academic interest and establishing first-line immunotherapy plus chemotherapy as the standard of care for advanced gastric cancer in China. Today, nivolumab in combination with chemotherapy has been approved as a first-line treatment for advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), and esophageal adenocarcinoma (EAC) in more than 50 countries, including the United States and China.